Immune thrombocytopenia guidelines get an annual checkup

In this issue of Blood Advances, Neunert et al 1 report on their systematic review of the literature performed to determine the need to revise or update the 2019 American Society of Hematology guidelines for immune thrombocytopenia (ITP). 2 In this field with multiple novel therapies on the horizon and many new publications reporting on potential important mechanisms of disease and targets for therapy, 3,4 the group looked to reassess the validity of the provided guidance.The findings indicate that although new evidence has emerged, it is insufficient to dramatically change the current guidelines or justify a full guideline revision.This article discusses the results of the literature review and the recommendations for changes to the guideline, especially suggesting clarification of second-line therapies in adults with ITP and updates to several other recommendations.